China Biopharmaceuticals: "TDI01" clinical trial application was accepted by CDE.

Introduction: TDI01 is an innovative therapeutic fibrosis drug developed by China Biopharmaceuticals.
2nd, China Biopharmaceuticals announced that TDI01, an innovative drug for fibrosis developed by its group, has been sent to the Drug Inspection Center (CDE) of the State Drug Administration of the People's Republic of China.
the innovative drug was approved by the U.S. Food and Drug Administration earlier this year for a new trial and is now being piloted locally in Phase I clinically anticipated trials.
TDI01 is a new target, highly selective Rhho / Rho-related polar helical formation protein kinase 2 (ROCK2) inhibitors, the country's 13th Five-Year Major New Drug Creations, currently conducting clinical trials of the adaptation of non-alcoholic abnormal hepatitis, pulmonary fibrosis.
fibrosis is due to loss in liver, lung and kidney fibrosis, residual trace tissue out of control will gradually guide TDI01 by inhibiting ROCK2, at the same time has inhibited fibrosis process, anti-inflammatory and immunomodulation effect, the development of fibrosis multiple segments of dual therapeutic effects.
.